MedTech Innovator

Samay specializes in remote respiratory health management. It develops AI-enabled wearable devices that monitor pulmonary volumes, trapped air, heart rates, breathing sounds, and lung temperature. This enables users to analyze their respiratory data and helps prevent respiratory diseases.

APrevent Medical Inc. is a medical device company founded in 2014 and headquartered in Taipei, Taiwan, with an additional office in Austria. The company specializes in developing therapeutic medical devices aimed at enhancing the quality of life for patients suffering from speech disorders. APrevent Medical focuses on innovative solutions, including a long-term implant system and a speech conversion platform, designed to provide minimally invasive treatments and support for voice and communication issues. By integrating advanced technologies, the company aims to offer effective interventions that enable patients to improve their speech capabilities and overall communication.

Cellular Vehicles develops hardware and software solutions that automate and standardize the final stages of cell and gene therapy delivery. The company focuses on the cell therapy industry, creating products that control the handling, preparation, and administration of cell‑based medicines. By measuring performance across variables such as localization, visibility, functionality, engraftment, and persistence, Cellular Vehicles provides a research model that supports medical professionals in delivering therapies efficiently and safely. Its mission is to accelerate the transition to curative cell‑based treatments, improve scalability and accessibility, and advance personalized medicine.

AusMed Global is an Australian life‑science company that develops non‑invasive breath‑sensing devices for home and point‑of‑care use. Its flagship product is a breath ketone analyzer that allows individuals to monitor ketone levels at home, supporting management of diabetes, obesity, and weight‑loss goals. The system uses disposable testing kits and interchangeable breath bottles, making it personalized, convenient, and easy to use.

Dopl specializes in telehealth solutions, focusing on improving healthcare outcomes for underserved areas. Co-founded by a former Microsoft engineer and Harvard-trained specialists, Dopl's core product is a telerobotic ultrasound system that enables remote diagnostic procedures, increasing patient access to care, enhancing outcomes, and benefiting hospitals through augmented workforce capabilities.

Fasciotens is a medical technology company based in Essen, Germany, focused on open abdomen therapy. The company develops a medical device designed to treat patients requiring an open abdomen by keeping the abdominal wall under tension and regulating intraabdominal volume, combining mesh-mediated traction with an external fixator concept to improve survival in critically ill patients. The device aims to prevent retraction of the abdominal wall and enable delayed closure, addressing situations such as abdominal compartment syndrome, severe infections, postoperative complications, or trauma.

Orthomod develops implantable composites that combine osteoactive additives with high‑strength thermoplastic carriers. Its proprietary platform merges natural and synthetic orthobiologics with polymer components to produce implants for orthopedic and spinal procedures. The company aims to enhance patient outcomes by delivering next‑generation structural biomaterials that support bone healing and joint stability, potentially transforming spine surgery, orthopedics, and prosthodontics.

CytoVeris develops optical-based technologies that assist surgical oncologists in identifying and removing tumor tissue during cancer resection surgery. Its devices enhance surgeons' ability to achieve clean margins, while its OncoMap system detects molecular signatures unique to cancer cells. Founded by Alan Kersey in Farmington, Connecticut in 2018.

myBiometry is developing a platform to monitor/manage patients with chronic disease using biomarker data from proprietary sensors and ML to identify patients at risk of treatment failure. Our initial focus is asthma where treatment failure occurs over 46% of the time (11.5M US patients, $80 billion). We are developing a single use, disposable sensor and device to track a biomarker of inflammation in breath. The data determines changes in adherence, treatment response, and risk of attack.

CancerFree Biotech is a startup focused on personalized cancer treatment, developing circulating tumor cell derived organoid platforms to model cancer and guide therapy. The company cultures and expands circulating tumor cells into organoids to help physicians tailor treatment plans across cancer stages, reducing ineffective drug use. Its E.V.A. technology combines organoid culture with artificial intelligence image recognition to rapidly transform circulating tumor cells into cancer derived organoids for applications in cell therapy, cancer vaccines, and new drug development. The platform supports predicting patient responses to therapies and enables pharmaceutical companies to identify effective treatments, with the goal of improving patient outcomes.

Ortho-tag is a developer of innovative in-vivo platforms that facilitate the connection between digital health applications and implanted biosensors within the human body. The company's technologies focus on enhancing wireless communication with medical devices through proprietary transcutaneous volume conduction. This enables real-time data exchange, in-vivo storage, and the integration of nanodiagnostic and therapeutic functions in smart medical implants. By providing a comprehensive system for wireless communication and data management, Ortho-tag supports medical device developers in advancing the capabilities of healthcare technology.

iCE Neurosystems is a developer of an advanced neuromonitoring platform aimed at enhancing the diagnosis and treatment of brain injuries. The company combines innovative devices, cutting-edge software, and big-data analytics to deliver real-time insights into brain health. This integration enables healthcare professionals to receive early warnings and guide treatment for patients suffering from brain injuries, particularly in critical care settings. By providing revolutionary insights, iCE Neurosystems enhances the ability of doctors and nurses to diagnose and prevent brain injuries more effectively.

Flow Medical develops a thrombolysis catheter designed to treat pulmonary embolism. Its catheter improves clot visualization, delivers medication directly to the blockage, and monitors treatment progress in real-time, enabling personalized therapy.

Acorai develops a non-invasive heart failure monitoring platform centered around direct intracardiac pressure monitoring. Its patented technology combines sensor technologies and machine learning to enable accurate, cost-efficient care, reducing re-hospitalization and mortality rates.

TYBR Health is a medical device company that develops a sprayable hydrogel to reduce internal scarring after surgery. The hydrogel, derived from natural sources, has shown a 75% reduction in scarring in preclinical studies. It is applied through a steerable device that can be used in both open and minimally invasive procedures, helping surgeons protect healing tissues and improve recovery outcomes. Founded in 2020 by Tim Keane and Alex Smith in Houston, Texas, the company focuses on simplifying postoperative care and enhancing the healing response of internal organs.

Hada Medtech is a Canadian medical device company headquartered in Guelph that develops airway management solutions designed to reduce intubation injuries and improve safety and efficiency for clinicians. Its products focus on enhancing patient care during airway procedures by providing innovative tools that mitigate risks associated with intubation. The company operates globally, delivering its technology to healthcare providers worldwide.

Craif develops innovative devices for early cancer detection using urine tests. Founded in 2018, the company aims to improve cancer survival rates by enabling painless, accurate, and regular diagnosis through its MicroRNA technology.

Nanochon is developing an implantable, 3D-printed cartilage implant designed to replace damaged cartilage and promote new tissue growth in joints, with a focus on knee damage. The device combines 3D printing and a novel nanomaterial to enable on-demand, cost-effective solutions intended to restore joint function and improve outcomes for young and active patients.

Spiorad Medical develops a medical device that simplifies the closure of large femoral artery access sites, ranging from 12F to 24F, used during catheter-based cardiac procedures. The device aims to improve clinical outcomes and accelerate patient recovery by providing a reliable method for sealing the artery after intervention.

Nurami Medical Ltd., established in 2014 and based in Haifa, Israel, is a clinical-stage medical device company specializing in the development of innovative solutions for soft tissue repair and regeneration following surgeries. The company's flagship product is a dural substitute patch, designed to replace damaged dura mater during neurosurgeries, promoting enhanced healing and patient recovery. Nurami's technology, based on electrospinning, creates a porous scaffold matrix that facilitates tissue regeneration and incorporates a temperature-sensitive sealant to prevent infections and cerebrospinal fluid leaks. The company aims to address unmet surgical needs and improve patient outcomes across various surgical procedures.

Gyder Surgical is an Australian medical technology company that develops intuitive, non‑invasive navigation systems for orthopaedic surgery. Its flagship product is an intra‑operative navigation platform that assists surgeons in accurately positioning implants during procedures such as total hip arthroplasty. The system is designed to be simple to use, requiring minimal changes to existing surgical workflows, and aims to improve surgical precision and patient outcomes across a range of care settings, from ambulatory surgery centers to large hospital operating rooms.

CardioSignal develops innovative solutions for detecting heart diseases. Its flagship product is a mobile application certified as a medical device for atrial fibrillation detection, built on over a decade of research.

InterMag is a medical technology company that develops magnetic navigation systems for minimally invasive procedures. By combining a robotic arm with magnetic fields, it precisely steers catheters or capsule endoscopes, enabling clinicians to perform examinations and interventions with higher accuracy and reduced radiation exposure for both staff and patients.

Vonova, established in 2022, specializes in developing a less invasive catheter-based technology for brain interfaces. Their flagship product, the Cerebro Atlas System, aims to provide neuromodulation therapy for chronic pain and other neurological disorders, replacing the need for high-risk, invasive brain surgery. The company, led by experts in catheter device development and neurology, has secured US patents, received an NIH grant, and been selected for the MedTech Innovator cohort 2024. Vonova's mission is to revolutionize the $2B+ brain interface market by offering a safer and more comfortable alternative to traditional methods.

Invicta Medical develops innovative medical technologies for advanced sleep apnea treatments. Founded in 2013, the company is headquartered in Santa Clara, California.

Armastec specializes in ergonomic wearables. Its flagship product is AireLevate, a vest designed to minimize lower back injuries by providing active support during manual handling tasks.

RNT Health Insights develops an AI-assisted software as a medical device (SaMD) solution for early gastric cancer detection. This technology, granted FDA Breakthrough Device Designation, improves efficiency and accuracy in real-time during endoscopic procedures, with preclinical validation showing 96% accuracy in detecting lesions indicative of gastric cancer.

Innova Vascular develops medical devices that treat vascular disease, focusing on removing clots in venous thromboembolism patients such as pulmonary embolism and deep vein thrombosis. The company’s products use a minimally invasive approach, allowing healthcare professionals to address clot‑related conditions efficiently while reducing patient recovery time.

Ligence is a Deep Tech startup based in Lithuania that combines medical expertise with artificial intelligence to automate echocardiography image analysis. The company develops tools for automatic recognition of heart image views, measurement, and report generation, accessible via a web-based platform and designed to integrate with hospital information systems. Its flagship solution, Ligence Heart, aims to reduce manual measurements by physicians and enhance consistency in heart ultrasound examinations through automated analysis. The offering targets clinicians and healthcare providers seeking to streamline cardiovascular imaging workflows.

NeuroBionics is developing advanced neural interface technology. Its key innovation lies in microscale, flexible bioelectronic fibers that combine electrical, chemical, and optical capabilities to sense and modulate biological environments. This enables researchers and medical professionals to enhance therapeutic interventions and develop novel treatments for neurological disorders.

Swift Duct develops a navigational tool for the ERCP procedure, which minimizes the risk of infections in the pancreas.

HealthTech Connex is a brain technology company based in the Health and Technology District. It specializes in translational neuroscience innovations aimed at improving neurological performance and overall health outcomes. The company's technology evaluates an individual's cognitive brain health across various conditions, including brain injuries, neurological diseases, and optimization. This enables mental health professionals to detect cognitive impairments related to mental health issues early. By bridging the gap between laboratory capabilities and real-world applications, HealthTech Connex provides valuable services to care and community sectors globally.

iNAP Sleep specializes in providing innovative solutions for individuals suffering from obstructive sleep apnea (OSA). The company offers a unique oral negative pressure device designed to treat OSA in adults. This system includes a soft, flexible mouthpiece and thin tubing, eliminating the need for traditional CPAP masks and enhancing user comfort. iNAP Sleep's approach promotes nasal breathing and is clinically proven to aid in the effective management of sleep apnea. The company also provides a mobile app, iNAP Lab+, for enhanced user experience and convenience, allowing for easy monitoring and management of therapy. iNAP Sleep's products are available for purchase online, with an initial 3-month trial period for new users.

NeuSpera Medical Inc. is a company based in San Jose, California, that specializes in the development and manufacturing of ultra-miniaturized implantable devices designed for neuromodulation therapy. Established in 2013, NeuSpera Medical utilizes its proprietary Mid-Field Powering technology, which harnesses the body as a natural waveguide to transmit energy, allowing for external powering of its implants. This innovative approach facilitates minimally invasive interventions aimed at treating chronic conditions such as Urinary Urgency Incontinence and chronic peripheral nerve pain. The company's focus on bioelectronic medicine positions it as a key player in advancing therapeutic solutions through its cutting-edge implantable technology.

Alfaleus Technology specializes in developing innovative eye care products and services. Their focus is on making eye care more accessible, affordable, and effective through cutting-edge technology.

Robeaute is a research and development agency that develops neurosurgical microrobots that can adapt to different types of medical evidence.

BrainSpace collaborates with physicians, families, financial backers, and other parties with the purpose of eliminating the long-term handicap brought on by brain injury.

Akeyna designs and produces medical devices that enhance patient safety during injections. Its flagship needle incorporates a vessel‑detection system that identifies blood vessels in real time, reducing the risk of complications such as blindness caused by accidental occlusion during procedures like dermal filler injections. By providing clinicians with precise, real‑time feedback, the company aims to improve outcomes and reduce adverse events in therapeutic and cosmetic applications.

Bloom43 specializes in supraphysiological preconditioning technology designed to help patients prepare and safeguard their bodies before surgery. Its unique device aims to prevent surgical complications by providing preconditioning therapy.

Astek Diagnostics is a healthcare company that develops precision diagnostic technology aimed at improving the diagnosis and treatment of bacterial infections. The company has created a platform that assists physicians in prescribing the correct antibiotics for patients suffering from bacterial sepsis within one hour. Utilizing a single-use cartridge, Astek Diagnostics' device identifies bacterial infections in urine by measuring the oxygen consumption of bacterial species, significantly reducing the turnaround time for results. This innovative approach not only facilitates timely treatment but also helps combat antibiotic resistance through effective susceptibility testing.

REMEDI is a solution provider for radiotherapy and radiography.

Founded in 2018, Aurie is a medical device company specializing in reusable urinary catheterization systems. Its flagship product is a portable, battery-operated case that washes, dries, and stores catheters, enabling individuals with mobility or neurological conditions to perform safe and independent urinary care.

INIA Biosciences is a developer of innovative medical devices that leverage sound wave technology to create non-invasive, home-administered systems for managing chronic inflammatory diseases. The company focuses on a closed-loop monitoring system designed to treat and prevent organ failure by integrating biomarker monitoring with an ultrasound stimulator. This approach aims to reduce inflammation linked to transplant rejection rates and minimize reliance on immunosuppressant drugs. By providing novel diagnostic sensing capabilities, INIA Biosciences enables physicians to better manage chronic diseases and improve patient outcomes.

FemTherapeutics is a Montreal-based medical device company dedicated to personalizing therapeutics in women’s health. It uses artificial intelligence and patient data to design customized gynecological prosthetics, initially focusing on improving the management of Pelvic Floor Disorders.

Padmaseetha Technologies develops portable, digitally connected peritoneal dialysis cyclers that enable patients to manage dialysis at home. The devices link to a cloud-based patient management system, allowing clinicians to monitor data remotely and adjust treatment without requiring hospital visits. The company emphasizes research-driven, cost-effective solutions for renal care worldwide.

Cyted specializes in digital diagnostic infrastructure, utilizing AI and innovative biomarkers for early disease detection. Its mission is to transform diagnostic methods, aiming for a world where diseases are prevented rather than treated.

NIRAMAI Health Analytix Private Limited is a Bengaluru-based company that specializes in cancer screening through its innovative software, Thermalytix, which leverages machine intelligence to analyze thermography images. Founded in 2016, the company offers a range of hardware-software solutions tailored for various users, including a compact screening device for specialty hospitals, a handheld device for independent medical practitioners, and a portable solution designed for large-scale screenings. NIRAMAI's technology enables early detection of breast cancer, identifying tumors significantly smaller than those detectable by traditional methods. Their approach is non-contact, painless, and free of radiation, making it a low-cost and accessible option for women of all age groups to undergo frequent screenings without adverse effects. By facilitating early diagnosis, NIRAMAI aims to improve survival rates and enhance the quality of cancer care.

Sydney Heart Valve is a health care company.

EndoVision Limited, established in 2018 and headquartered in Hong Kong, specializes in the development of advanced artificial intelligence software aimed at enhancing computer-aided diagnosis in endoscopy. The company's innovative technology integrates AI to improve diagnostic accuracy and efficiency, positioning it as a significant player in the medical technology sector. Through its focus on leveraging artificial intelligence, EndoVision seeks to transform endoscopic procedures and contribute to better patient outcomes in the healthcare industry.

AccurKardia is an innovative company specializing in ECG-led diagnostics software. It transforms ECG data into a powerful tool to improve patient outcomes globally, with initial applications in cardiology. The company offers AccurECG™, an FDA-cleared Class II software as a medical device (SaMD) for automated, near real-time ECG interpretation. Its AI-driven hyperkalemia detection solution, AK+ Guard™, received FDA Breakthrough Device Designation.

Ozlo Sleep is a science-driven sleep and audio technology company that supports and simplifies sleep rituals for clinical benefits, without the use of medication.

Butterfly Medical Ltd is a medical-device company founded in 2014 and based in Yokne'am, Israel. It specializes in the development of an implantable device aimed at treating Benign Prostatic Hyperplasia (BPH), a condition commonly referred to as enlarged prostate. The company's innovative device provides a fast, simple, and minimally invasive alternative to conventional BPH treatments, including medications and surgery. It can be implanted in under ten minutes in an office setting using local anesthesia, without the need for surgical incisions or removal of prostate tissue. This approach not only minimizes side effects but also eliminates the requirement for hospitalization or general anesthesia. Initial clinical trials have shown promising results, with effective outcomes in opening blocked urethras and no reported side effects. Butterfly Medical is advancing further clinical studies in leading medical centers across Europe to validate its device's efficacy and safety.

Relief Cardiovascular develops an innovative smart implant designed to monitor and modulate blood flow, aiming to reduce congestion in the heart and potentially improve outcomes for patients with congestive heart failure.

ATDev specializes in assistive technology and medical devices, focusing on mobility solutions. It develops robotic devices designed to enhance physical therapy accessibility and outcomes, enabling remote patient monitoring through telehealth services.

Qritive is a technology company that offers an artificial intelligence-powered diagnostic platform aimed at enhancing the accuracy and efficiency of cancer diagnoses. By utilizing advanced AI and natural language processing, Qritive's solution enables medical professionals to analyze microscopy images alongside patients' medical histories. This innovative approach allows hospitals to streamline their diagnostic processes, ultimately reducing costs and improving patient outcomes. With the rising incidence of cancer, Qritive addresses a critical need in the healthcare sector, equipping doctors with modern tools to aid in timely and precise cancer detection.

Droppet IV develops a medical device that automatically flushes intravenous (IV) sets at the precise moment medication administration ends. This innovation enhances patient care by ensuring optimal treatment and reduces nursing workload.

Founded in 2015, DiaMonTech specializes in developing non-invasive medical diagnostic devices. Its proprietary photo-thermal detection technology enables accurate glucose level measurements without finger pricking or blood samples.

Samay specializes in remote respiratory health management. It develops AI-enabled wearable devices that monitor pulmonary volumes, trapped air, heart rates, breathing sounds, and lung temperature. This enables users to analyze their respiratory data and helps prevent respiratory diseases.

INOPASE is a medical device company focused on developing wirelessly powered, closed-loop implantable neuromodulation systems. Currently, it specializes in the development of closed loop sacral neuromodulation for overactive bladder treatment and closed loop brain neuromodulation for epilepsy management.

KA Imaging designs and manufactures advanced X-ray detectors for medical and industrial applications. Its products include static detectors for pipe inspection, dual-energy detectors for baggage screening, dynamic detectors for engine inspection, and mammography detectors. The company's flagship product, Reveal, is a portable dual-energy subtraction X-ray detector cleared by the FDA, offering improved disease detection capabilities. Founded in 2015, KA Imaging is headquartered in Waterloo, Canada.

Lattice Medical is a French medical device company focused on breast reconstruction after cancer. It designs and manufactures implantable devices that promote regeneration of autologous adipose tissue to enable natural breast reconstruction following mastectomy. The flagship implant, MATTISSE, uses 3D printing and fully biodegradable materials to provide personalized reconstruction in a single surgery, reducing operative time and invasiveness. The company aims to offer an alternative to silicone-based implants by supporting tissue regeneration rather than replacement. Founded in 2017 and based in Loos, France, Lattice Medical develops solutions to address clinical and societal needs by restoring form and function for women recovering from breast cancer.

Founded in 2005, Arsenal Medical develops innovative polymer-based materials for treating vascular diseases. Its primary products include therapeutic foams for managing acute hemorrhage and AxioCore nanofiber technology for cell integration and tissue regeneration. The company focuses on improving local therapy for injury and disease using conventional biomaterials in unconventional ways.

FibriCheck is a medically certified software-as-a-medical-device that detects irregular heart rhythms, including atrial fibrillation, through a smartphone camera. The app operates as a software-only solution on prescription, enabling users to measure cardiac rhythm anywhere and anytime, with data automatically shared with a medical professional to support faster diagnosis and appropriate treatment plans. The company leverages artificial intelligence to locate and track heart rhythm issues and to assist in managing conditions such as high blood pressure and heart failure, aiming to revolutionize cardiovascular care and empower patients to monitor and manage their heart health efficiently.

Salvia BioElectronics B.V., founded in 2017 and based in Eindhoven, the Netherlands, specializes in developing bioelectronic therapies aimed at alleviating chronic neurological diseases, particularly chronic migraines. The company seeks to deliver innovative, drug-free solutions that restore health while minimizing side effects. The name "Salvia," derived from the Latin word for health, reflects the company's commitment to well-being, paralleling the historical use of the Salvia plant in treating ailments like headaches and mental disorders. Salvia BioElectronics is driven by a team of experienced professionals from diverse backgrounds in the medical device industry, including notable companies such as Medtronic and Philips, who collaborate to make effective bioelectronic treatments widely accessible.

Avance Innovations develops the patented ORASIS microsurgical device, a 3‑D‑printed system that delivers continuous, autonomous irrigation and suction during surgery. The technology enhances safety, precision, and cost‑effectiveness by reducing operative time and improving vessel visibility for surgeons.

Prevencio is a biotechnology company focused on developing innovative multi-proteomic biomarkers aimed at transforming blood tests for cardiovascular disease. Utilizing artificial intelligence, the company's biomarkers analyze established clinical data sets to create novel, multi-protein tests that are algorithmically scored. These tests enable clinicians to evaluate the effects of medications before and after administration, specifically concerning a composite risk of heart attack, stroke, and cardiac death. By leveraging advanced technology in biomarker development, Prevencio seeks to enhance the accuracy and effectiveness of cardiovascular diagnostics.

Summa Therapeutics is a medical device company that produces injectable angioplasty balloon catheters. Summa Therapeutics is a commercial-stage medical device startup dedicated to innovation and driving remarkable advancements in vascular patient care.

The Shape Sensing Company specializes in advanced fiber optic 3D guidance technology that enables physicians to navigate medical devices within patient-specific anatomical models. Primarily focused on enhancing endovascular procedures, the company's innovative platform allows vascular surgeons and interventional radiologists to efficiently conduct approximately 2.8 million procedures annually in the United States, utilizing a proprietary 3D guidance workstation and guidewire. This technology not only aims to reduce procedure times and operational costs but also enhances patient outcomes by eliminating reliance on traditional X-ray imaging. Beyond its initial applications in medicine, The Shape Sensing Company is also poised to expand its impact across multiple industries, including aerospace, civil engineering, mining, and energy, through collaborations with various Original Equipment Manufacturer (OEM) partners developing 3D-guided devices.

Taurus Vascular is a medical device company dedicated to enhancing long-term outcomes for patients suffering from aortic aneurysms. The company is focused on transforming the standard of care by developing innovative medical device technology aimed at addressing the complications associated with endoleaks. This technology is designed to facilitate accelerated shrinkage of the aneurysm sac following endovascular aortic aneurysm repair (EVAR). By improving the effectiveness of treatment, Taurus Vascular aims to significantly enhance patient outcomes in the healthcare sector.

Founded in 2019, Solenic Medical specializes in the development of a non-invasive medical device that uses alternating magnetic fields to eradicate biofilm on metallic implants. Its technology aims to address complications arising from surgeries like knee and hip replacements, as well as trauma-related implants.

Nanotis Corporation, founded in 2016 and based in Tokyo, Japan, specializes in the development of instant diagnostic devices aimed at addressing challenges in infectious disease testing, particularly for influenza. The company manufactures microchip-based devices that allow users to quickly and accurately diagnose illnesses. By providing early diagnosis solutions, Nanotis supports medical professionals in practical healthcare settings, thereby enhancing the efficiency of healthcare delivery and improving patient outcomes.

Surgical Automations specializes in the development of surgical robots and automation technologies aimed at improving patient safety and reducing medical errors. The company offers an AI-based autonomous robotic navigation system tailored for endoscopic diagnostic and interventional procedures. Their innovative approach includes an automated endotracheal intubation system that accurately detects the trachea's opening and facilitates the insertion of the endotracheal tube. This technology significantly enhances the precision of surgical procedures, enabling medical professionals to minimize risks and improve outcomes during operations.

Founded in 2015, Nanobiofab specializes in manufacturing smart, nanotech-based wearable healthcare devices for humans and pets. Its flagship product, iNose, detects and monitors skin vapor-print wirelessly via mobile phone, tracking fat burning rate, exercise effectiveness, and metabolic rate over time.

CranioSense develops non-invasive medical devices to diagnose and monitor intracranial hypertension, providing clinicians with crucial insights for treating neurological conditions.

Laguna Tech USA is a medical device company that designs and develops heart valve replacement systems aimed at treating aortic and mitral regurgitation and aortic stenosis. Its flagship device integrates balloon-expandable and self-expanding technologies to provide a simple, reliable, and precisely deployable solution for minimally invasive procedures, improving patient outcomes.

Founded in 2019, Promedius specializes in developing innovative solutions for the early detection and management of musculoskeletal diseases like osteoporosis. Its flagship product, PROS® CXR:OSTEO, uses AI to analyze chest X-ray images, enabling healthcare providers to identify patients at risk of osteoporosis.

Endo-Tagss produces and sells a novel trans-abdominal gastric access device for surgical instruments.

Juniper Biomedical is a medical device company focused on implantable neuromodulation technology aimed at addressing pelvic health conditions. The company develops micro-implants that deliver targeted treatment by stimulating specific nerves, allowing for local modulation of innervation to muscles and organs. This innovative approach enables the provision of less invasive, safer, and more effective therapies for various conditions, including incontinence, sexual dysfunction, and chronic pain. By concentrating on precision treatment, Juniper Biomedical seeks to improve patient outcomes and enhance quality of life for individuals suffering from these health issues.

Neurovalens is a UK-based company founded in 2013 that specializes in developing medical devices grounded in neuroscience, bioscience, and neurophysiology. The company's portfolio includes Stimu Slim and Modius, electronic headsets designed to address obesity through non-invasive neurostimulation. Neurovalens' technology focuses on transdermal activation of key brain regions to modulate autonomic function, circadian rhythms, and metabolic processes, offering healthcare providers drug-free treatment options for various health conditions. The company has received support from Invest NI under the European Union’s Investment for Growth and Jobs Programme to enhance its research and development activities.

Artificial intelligence driven software applications for digital health technologies. We train multimodal systems to be able to execute automated administration optimisation tasks as well as repetitive patient monitoring and classification solutions. We work closely with the NHS.

IFPx develops an implantable patient monitoring device that directly analyzes fluid buildup in the body. This device aims to improve the management of chronic illnesses, initially focusing on heart failure.

Newrotex is an Oxford-based small and medium-sized enterprise specializing in the development of an innovative silk-based conduit designed for the repair of peripheral nerve injuries. The company has created an off-the-shelf device that allows for immediate treatment of patients who have experienced nerve damage due to trauma or cancer surgery. This approach eliminates the risks associated with traditional autograft treatments, which often lead to significant morbidity. By providing healthcare professionals with an effective alternative, Newrotex aims to enhance patient outcomes in the treatment of peripheral nerve injuries.

StrokeDx is a company that specializes in the development of innovative and portable diagnostic devices aimed at revolutionizing stroke care. Through the use of advanced microsensors and artificial intelligence, StrokeDx's products can quickly detect blood presence in the brain, generating predictive images of stroke locations after scanning. This technology significantly reduces the time to treatment for stroke patients and is designed to be more cost-effective than traditional diagnostic methods. The company employs a dedicated software engineering team focused on creating novel algorithms that enhance the diagnostic accuracy and imaging capabilities of its devices, ultimately improving the triage and diagnosis process for healthcare providers.

Fingy3D is a company focused on making prosthetic devices accessible to all, specifically targeting the need for finger prosthetics. Utilizing an AI scanner, Fingy3D measures the dimensions of an individual's finger to create a custom-fit prosthetic. This innovative approach allows customers to receive 3D-printed prosthetic fingers conveniently at their doorsteps, enhancing the quality of life for those in need of such devices.

Neurava specializes in developing wearable diagnostic devices for epilepsy patients. Their products monitor health metrics, alert users and healthcare providers to seizures and cardiorespiratory dysfunctions, enabling timely intervention and improved treatment outcomes.

Biotome is a biotechnology research firm focused on developing advanced antibody diagnostic tests. The company specializes in identifying markers that indicate a high risk of stomach cancer, aiming to provide more precise and detailed disease information compared to current screening methods. By leveraging next-generation technology and precision immunology, Biotome's tests are designed to enhance the ability of medical professionals to treat patients effectively.

MicroTransponder is a medical device company that develops and commercializes implantable neurostimulation platforms aimed at treating neurological conditions. The company focuses on vagus nerve stimulation to promote neuroplasticity and functional recovery, with products including the Serenity System for tinnitus and Vivistim, an FDA-approved therapy for ischemic stroke survivors with moderate to severe upper-limb impairment more than six months post-stroke. Founded in 2007 and headquartered in Austin, Texas, MicroTransponder's technology combines paired vagus nerve stimulation with wireless delivery of targeted electrical impulses to enhance recovery after neurological injury and disease.

Proton Intelligence develops a wearable device that monitors potassium levels in real-time via interstitial fluid, closely correlated to blood. This enables clinicians and patients to manage medications and diets effectively for improved heart and kidney care, particularly targeting hyperkalemia in chronic kidney disease patients with co-morbidities.

Flow Neuroscience, established in 2011 and based in Malmö, Sweden, specializes in developing and manufacturing a wearable device and accompanying mobile application for medication-free treatment of depression. The company's core product is a transcranial direct current stimulation (tDCS) headset that targets the left frontal lobe, an area of the brain often associated with depression. This non-invasive treatment is complemented by a personalized mobile app that encourages users to adopt healthier daily routines, such as regular exercise and sleep patterns, to help alleviate depressive symptoms. Flow Neuroscience aims to make this innovative, affordable treatment accessible to the public, challenging the dominance of pharmaceuticals in mental health care.

Xcision Medical Systems develops advanced stereotactic radiotherapy solutions for treating breast cancer. Its radiosurgery device delivers gamma irradiation, enabling a single, non-invasive treatment session instead of weeks-long courses, reducing radiation exposure to surrounding tissues and allowing patients to resume normal lives more quickly.

PanTher Therapeutics is a biotechnology company developing cancer drug-delivery technologies. Its core platform enables therapeutics to be delivered directly to the tumor site, reducing systemic toxicity and allowing higher drug concentrations at the target while enabling sustained treatment. This approach aims to improve therapeutic efficacy and outcomes for hard-to-treat cancers by maximizing drug exposure at the tumor while limiting exposure to healthy tissue. Headquartered in Cambridge, Massachusetts, PanTher Therapeutics is advancing investigational candidates, including a lead program in pancreatic cancer, to broaden the potential of precision delivery in oncology.

Neurava specializes in developing wearable diagnostic devices for epilepsy patients. Their products monitor health metrics, alert users and healthcare providers to seizures and cardiorespiratory dysfunctions, enabling timely intervention and improved treatment outcomes.

Perceptive Medical is a developer of advanced medical devices aimed at enhancing blood pressure management in critical care settings, such as the intensive care unit (ICU) and operating room. The company's products are designed to integrate seamlessly into modern clinical workflows, providing healthcare providers with precise tools to address inefficiencies in patient care. By focusing on delivering measurable improvements in blood pressure therapy, Perceptive Medical plays a vital role in optimizing patient outcomes and supporting clinical professionals in their efforts to enhance overall care efficiency.

Xtremedy Medical, based at NUI Galway, specializes in manufacturing innovative surgical devices. These devices use electrical signals to treat bone and deep tissue infections, including diabetic foot ulcers. By targeting both surface and underlying infections, the company's technology helps doctors enhance treatment outcomes, reducing the risk of amputations and promoting faster patient recovery.

Inbrain Neuroelectronics is a medical device company that designs and commercializes graphene-based neural interfaces and intelligent neuromodulation systems to treat brain disorders. The core platform is an implantable system that decodes brain activity with high resolution and provides focal, adaptive stimulation, enabling real-time precision neurology and autonomous therapy adjustments. This approach aims to maximize therapeutic outcomes while minimizing side effects for conditions such as Parkinson’s disease, epilepsy, and stroke rehabilitation. The company pursues strategic collaborations to extend its solutions to peripheral nerve and systemic disease applications, expanding the potential of neurotechnology and bioelectronics.

ImmersiveTouch Inc., established in Chicago, Illinois in 2005, specializes in developing, installing, and managing virtual reality simulators for medical training and patient engagement. The company's core offering is a high-fidelity immersive surgical simulator, housed within an 'immersive pod', which enables surgeons to interact with realistic 3D computer-generated anatomical models using haptic instrument replicas. This system provides lifelike visual, tactile, and audio sensations, facilitating skill development and pre-operative planning across various medical specialties such as core surgery skills, neurological surgery, spine, and ophthalmology. Additionally, ImmersiveTouch has expanded its offerings to include AI-driven digital surgery platforms, the Ikshana XR platform, which provides clinicians with data insights to enhance decision-making, improve patient outcomes, and optimize surgical resource allocation.

Covellus is a medical device company focused on developing innovative platform technology for catheters used in minimally invasive surgeries. The company specializes in manufacturing vascular catheter devices and modular catheter systems, which allow physicians to customize existing devices to meet the specific needs of individual patients. By enhancing the versatility and adaptability of medical devices, Covellus aims to improve treatment outcomes in various medical procedures.

Endocision is a medical device company focused on creating innovative minimally-invasive technologies for the diagnosis and treatment of lung diseases. The company specializes in robotic bronchoscopy technologies and a cryo-biopsy platform, which enhance the safety and effectiveness of procedures used by healthcare professionals. Endocision's solutions aim to facilitate the diagnosis and management of conditions such as interstitial lung disease and lung cancer, thereby improving patient outcomes through advanced medical interventions.

Thermidas, a Finnish health technology company, specializes in developing and advancing infrared thermal imaging for diagnostic purposes. Its core product is thermal imaging software, designed to support screening, early diagnostics, and evaluation of treatment effectiveness. The technology enables swift and simple detection of asymmetric body temperature, which can indicate underlying health issues like inflammation, circulatory problems, and potential ulcers. This allows university hospitals and experienced clinicians to identify and diagnose conditions at earlier stages than traditional methods.

Opticyte, Inc. is a medical device company based in Seattle, Washington, specializing in the development of advanced algorithms and optical spectroscopy technology to monitor cellular oxygen levels. Founded in 2016 as a spinoff from the University of Washington, the company is focused on creating its first product, the Cell O2 Monitor, which aims to reduce the risk of organ failure. This innovative noninvasive oximeter measures oxygen levels within cells, enabling early detection of critical conditions such as shock, sepsis, hemorrhage, and cardiac dysfunction. By providing clinicians with essential data, Opticyte's technology facilitates timely treatment decisions that can prevent multiple organ failure and improve patient outcomes. The company comprises teams with extensive experience in engineering, regulatory affairs, and communications, all dedicated to advancing medical device innovation.